Progering
Alternative Name: Progestin Vaginal Ring (PVR)
Description: A progestin only 3-month vaginal ring, marketed specifically for breastfeeding women. Given its short half-life orally, it is destroyed when ingested in mother's milk and there is no impact on the infant.
Product Details
Duration: 3 months
Regimen:
Dose: 10 mg
Active Pharmaceutical Ingredient (API):
Inactive material: elastomer
Status Details
Developer: ,
Began discovery in: mid-1990
Status Details: - Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
- Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
- It is under evaluation at WHO for the prequalification program at manufacturing site.
- It is now on the WHO's Essential Medicine list.
- Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
- Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
- It is under evaluation at WHO for the prequalification program at manufacturing site.
- It is now on the WHO's Essential Medicine list.
Additional Information
References: Population Council Website: http://www.popcouncil.org/research/the-progesterone-vaginal-ring-expandi...
Population Council Website: http://www.popcouncil.org/research/the-progesterone-vaginal-ring-expandi...